Cannabis and diabetes research is evolving quickly, but the evidence is not simple. Here is what Florida medical cannabis patients should know about blood sugar, product formats, terpenes, safety, and current research.

Humulene is an earthy, hoppy cannabis terpene being studied for appetite suppression and anti-inflammatory potential. Here’s what Florida medical cannabis patients should know before shopping by terpene profile.

Ocimene is a lesser-known cannabis terpene with a sweet, herbal, citrusy aroma and growing research interest. Here’s what Florida medical cannabis patients should know about its potential effects, medical relevance, and how to shop terpene-aware.

Fibromyalgia management is rarely about one solution. Here’s how medical cannabis may fit into a broader symptom-support plan, from balanced tinctures to targeted topicals.

If you have been paying closer attention to cannabis science lately, you have probably seen more conversation around acidic cannabinoids like THCA and CBDA. These are not trendy “new” compounds. They are the plant’s original forms. Cannabis naturally produces cannabinoid acids first, and those compounds convert over time or through heat into the better-known cannabinoids THC and CBD.

PTSD is one of those conditions that can make life feel smaller. Sleep gets lighter, your nervous system stays on high alert, and ordinary stress can suddenly feel anything but ordinary. That’s part of why cannabis keeps coming up in PTSD conversations. Patients want relief. They want something that feels practical. They want to know whether medical cannabis belongs in a real care plan or whether it just sounds promising online. For Florida patients, that question matters even more because PTSD is a qualifying condition in the state’s medical marijuana program, and a qualified physician decides whether cannabis is appropriate for your case.

The biggest 2025 headline: Rescheduling is back in motion

Late in 2025, President Donald Trump signed an executive order directing the Department of Justice to move more quickly on the ongoing process to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act.

That’s a big deal in cannabis policy terms—but it’s not the same as federal legalization.

Key point: Multiple legal and policy summaries emphasize that a final rule has not been issued, and until it is, marijuana remains Schedule I at the federal level.